Janux Therapeutics, Inc.

Janux Therapeutics, Inc.

NNASDAQ:JANX
10.92
USD
-0.45
(-3.96%)
-1.59EPS
1.06BMarket Cap
Mar 05Next Earn
Janux Therapeutics, Inc.
NASDAQ:JANX
(Nasdaq Stock Market)

Recent

price

10.92

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
USD
- -
- -
0.15
0.21
0.18
0.2
0.16
0.37
Revenue per Share
-0.62
-0.54
-1.39
-1.52
-1.32
-1.28
-1.83
-1.59
Basic EPS, GAAP
-0.6
-0.35
-0.78
-1.19
-1.19
-0.82
-1.34
-0.86
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.2
-0.37
8.88
7.71
7.44
17.32
15.85
14.9
Book Value per Share
-0.2
-0.37
8.88
7.71
7.44
17.32
15.85
14.9
Tangible Book Value per Share
6
12
24
41
44
54
62
63
Basic Weighted Avg Shares
- -
- -
4
9
8
11
10
23
Sales/Revenue/Turnover
- -
- -
-905.39
-779.04
-902.87
-933.58
-1,576.67
-599.26
Operating Margin (%)
- -
- -
- -
1
2
2
2
2
Depreciation Expense
-4
-7
-33
-63
-58
-69
-114
-100
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-898.32
-732.22
-721.18
-651.62
-1,136.25
-428.74
Profit Margin (%)
-4
13
364
316
336
1,016
951
905
Working Capital
- -
- -
- -
25
23
21
20
18
LT Debt
-8
-15
366
321
344
1,023
957
912
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-18.36
-17.53
-10.09
-11.48
-10.58
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
2
3
3
LT Borrowings
- -
- -
- -
LT Finance Leases
19
18
18
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
61
61
61
Market Capitalization
846
938
1,057

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,002
983
959
Cash, Cash Equivalents & STI
956
971
946
Accounts Receivable, Net
35
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
59
60
54
Payables & Accruals
17
19
20
ST Debt
2
3
3
Deferred Revenue
38
35
27

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-483.42%
-6.45%
Free Cash Flow
- -
113.78%
88.53%
Net Income, GAAP
- -
110.02%
64.69%
Sales/Revenue/Turnover
- -
- -
-5.55%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
9
- -
- -
11
2025
- -
- -
10
- -
10
2026
4
10
9
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.3
-0.11
-0.51
-0.36
-1.28
2025
-0.38
-0.55
-0.39
-0.51
-1.83
2026
-0.39
-0.35
-0.34
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Janux Therapeutics, Inc. Janux Therapeutics, Inc. (JANX) is a clinical-stage biopharmaceutical company that develops precision-engineered tumor-activated T cell engagers (TRACTr), T cell co-stimulatory inhibitors (TRACIr) and agonist receptor modulators (ARM) to treat cancer and autoimmune diseases by selectively modulating T cells while minimizing systemic toxicity. The company offers a broad pipeline of wholly owned and partnered product candidates, including JANX007, a PSMA-targeted TRACTr in Phase 1b expansion for metastatic castration-resistant prostate cancer (mCRPC) in taxane-naïve, taxane-experienced, PARP inhibitor-resistant and novel hormonal therapy-experienced patients; JANX008, an EGFR-targeted TRACTr in Phase 1 for solid tumors such as colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer; preclinical PSMAxCD28 TRACIr to enhance T cell survival with JANX007; TROP2-targeted TRACTr for TROP2-positive tumors; and CD19-ARM for autoimmune diseases with an investigational new drug application planned for late 2025; alongside partnered TRACTr programs with Merck & Co., Inc. Merck & Co., Inc. targeting epidermal growth factor receptor, prostate specific membrane antigen and trophoblast antigen 2. Janux Therapeutics, Inc. operates primarily in the United States with global development potential through collaborations, targets oncology and immunology patient populations with high unmet needs, and maintains headquarters in San Diego, California, where it was founded in 2017. Recent developments include the achievement of a clinical milestone in the TRACTr collaboration with Merck & Co., Inc. in August 2025, triggering milestone payments and advancing the first partnered program into Phase 1; initiation of Phase 1b expansion studies for JANX007 in May 2025 supported by Phase 1a data showing 100% PSA50 declines, 63% PSA90 declines and median radiographic progression-free survival of 7.5 months in 16 mCRPC patients; plans for additional Phase 1b studies combining JANX007 with androgen receptor inhibitors and updates on JANX007 and JANX008 in the second half of 2025; and progression of three preclinical programs toward the clinic in 2026.

Company News

  • Janux Therapeutics, Inc. (JANX) Discusses JANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy Transcript

  • Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease

  • Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Beats Revenue Estimates

  • Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

  • Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers

  • Janux Therapeutics (NASDAQ:JANX) and Zai Lab (NASDAQ:ZLAB) Head-To-Head Survey

  • Head-To-Head Review: Janux Therapeutics (NASDAQ:JANX) and Roivant Sciences (NASDAQ:ROIV)

  • 4 Prostate Cancer Drug Stocks to Watch During Awareness Month

  • Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

  • Here Are Monday’s Top Wall Street Analyst Research Calls: AstraZeneca, Celestica, Chipotle Mexican Grill, Domino’s Pizza, Fortune Brands, Golar LNG, Jersey Mike’s Subs, Roku, and More

  • JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know

  • Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates

  • Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

  • Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know

  • Here's Why You Should Add JANX Stock to Your Portfolio Now

  • Janux Therapeutics, Inc. (JANX) Reports Q1 Loss, Lags Revenue Estimates

  • Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

  • How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44%

  • Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value

  • Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development